Professor Park Joon-sik of obstetrics and gynecology at Soonchunhyang University Bucheon Hospital announced on the 14th that ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer ... Overall survival data isn’t yet mature.

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...

One reason is the fact that much research related to ovarian cancer has focused on strategies ... urgent need to improve strategies to prolong survival, especially for all patients in a first ...

The study reveals that AI systems offer promising accuracy in predicting treatment outcomes, particularly when used to ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...